Related Experiment Video

Updated: Nov 20, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

251

Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML

Abdullah Ladha1, Gavin Hui2, Edna Cheung3

  • 1Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

Leukemia & Lymphoma
|January 25, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K

Related Experiment Videos

Last Updated: Nov 20, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

251
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia.

Blood cancer discovery·2026

Healthcare Utilization After Biologic Initiation for Chronic Rhinosinusitis.

American journal of rhinology & allergy·2026

The Influence of Preoperative Mood Disorders on Postoperative Complications and Healthcare Utilization in Adolescent Sports Injuries.

Sports health·2026

A case of true acute eosinophilic leukemia arising from myelodysplastic syndrome.

Journal of hematopathology·2026

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal of hematology & oncology·2026

Effects of O-GlcNAc glycosylated modified transferase on prognosis of diffuse large B-cell lymphoma and analysis of downstream targets.

Leukemia & lymphoma·2026

Additional myelodysplasia-related gene mutations alter clinical presentation and worsen prognosis in patients with SRSF/TET2 co-mutated myeloid neoplasms.

Leukemia & lymphoma·2026

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.

Leukemia & lymphoma·2026

Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.

Leukemia & lymphoma·2026

A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.

Leukemia & lymphoma·2026

Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare.

Leukemia & lymphoma·2026

Regulatory T cells: From Foxp3 to tolerance-inducing therapies.

The Journal of investigative dermatology·2026

Prospective Evaluation of Ustekinumab Dose Intensification in Inflammatory Bowel Diseases.

Gastro hep advances·2026

Does imepitoin reduce signs of fear and anxiety in dogs frightened by loud noises?

Veterinary evidence·2026

Immunophenotyping, activation, and expansion of gamma delta T cells: flow cytometry profiling and ex vivo manipulation strategies.

Frontiers in immunology·2026

Correlation between the CD8+ T cell/IFN-γ axis and clinical disease progression at different phases of ITP.

Frontiers in pediatrics·2026

Clinical analysis of laparoscopic transabdominal preperitoneal hernioplasty (TAPP) for incarcerated inguinal hernia.

Medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us